Raising KRAS

How Wellspring, Janssen team showed potential of KRAS inhibitor for cancer

For the first time, a joint research team from Wellspring Biosciences LLC and the Janssen Research & Development unit of Johnson & Johnson (NYSE:JNJ) showed a small molecule K-Ras (KRAS) inhibitor worked in animal models of cancer. The results could pave the way for clinical development of a therapy against the target, a member of the notoriously “undruggable”

Read the full 583 word article

User Sign In